Corona Remedies FY26: 17% revenue, 33% PAT, beats IPM

Key takeaway for investors

Corona Remedies has reported FY26 performance that, by its own filings and management commentary, stayed ahead of the Indian pharmaceutical market (IPM) growth rate. India business revenue rose 17.18% in FY 2025-26 versus IPM growth of 8.59%, positioning the company as a faster-growing player within domestic formulations. Management also stated that FY26 revenue grew about 17% and profit after tax (PAT) increased 33% year-on-year, which was described as ahead of its guided range of 15% revenue growth and 20% PAT growth.

Alongside the headline growth numbers, the provided data points also capture multi-year growth trends and profitability indicators such as ROE and cash conversion. These metrics matter because Corona Remedies is operating in a market where chronic therapies, distribution depth, and disciplined spend can materially influence margins and repeat prescriptions.

FY26 growth versus guidance and IPM

The filing highlighted FY 2025-26 as a strong year, with India business revenue growth of 17.18% against IPM growth of 8.59%. Management commentary states this outperformance was ahead of the guided range of 15% revenue growth and 20% PAT growth. In the same commentary, revenue for FY26 was said to have grown 17% while PAT increased 33% year-on-year.

The company also reiterated a growth philosophy that targets 15% revenue growth and 20% profitability growth on a year-on-year basis over the coming three to five years. Separately, management said it expects to sustain 15% plus revenue growth organically and 25% revenue growth in acquired brands, along with 20% plus PAT growth in FY27 (the transcript reference shows “FY272”).

What the longer-term growth numbers indicate

The provided “Sales Growth” data shows compounded growth of 17.28% over one year, 16.65% over three years, and 19.49% over five years. “Profit Growth” is shown at 24.02% over one year, 29.71% over three years, and 21.45% over five years. A separate statement in the text reiterates that profit growth over the past three years was 29.7099% and revenue growth over the past three years was 16.6482%.

Profitability indicators in the same dataset include a three-year ROE of 25.0611%. The company’s cash flow management is also described as strong, with CFO/PAT at 1.52768828507608. Dividend payout is mentioned at 25.0%.

Latest reported financial line items (FY2024 and FY2025)

The dataset includes an annual snapshot with total revenue of ₹1,202.35 crore in FY2025 versus ₹1,020.93 crore in FY2024, with total revenue growth shown at 17.77% in FY2025 and 14.57% in FY2024. Total expenses are shown at ₹1,004.21 crore in FY2025 versus ₹902.46 crore in FY2024, and total expenses growth at 11.27%.

Another FY2025 snapshot states net sales increased 18% to ₹1,196.42 crore versus FY2024. Operating profit margin (OPM) improved by 481 bps to 20.06%, and operating profit rose 55% to ₹239.98 crore, with the drivers described as higher volumes from UAE, Kenya, and Venezuela.

Basic EPS is shown at ₹7.55 (listed as “Quarterly | Annual” in the provided line), while the FY2025 EPS on post-issue equity is stated as ₹24.4. At an upper price band of ₹1,062, the P/E is given as 43.

Business mix, geography, and distribution footprint

The text states India accounted for 96.34% of revenue in Q1 FY2026, while exports contributed 3.66%. Regionally, the company is described as having a strong presence in western India, covering Gujarat, Maharashtra, Goa, Madhya Pradesh, and Chhattisgarh. This western zone contributed 47.30% of total domestic sales in MAT June 2025.

These details help explain how domestic formulations remain the core earnings base, while exports are present but still a small share. The mention of specific states and a high contribution from the western zone points to an execution focus on key prescribing markets.

Portfolio shift toward chronic and sub-chronic therapies

Corona Remedies’ chronic and sub-chronic therapies segment expanded from 63.8% of total domestic sales in MAT June 2022 to 70% in MAT June 2025. Over the same period, the segment is stated to have grown at a 20.5% CAGR, which is described as more than double IPM growth of 10%.

The company’s strategy for further growth is described as increasing market share across key therapeutic areas by strengthening its chronic and sub-chronic portfolio and offering products across the patient life cycle. It also plans targeted new product launches addressing unmet needs, supported by brand extensions, acquisitions, and in-licensing opportunities for its India business.

Positioning versus IPM and peer set

The CRISIL Intelligence report reference in the text says Corona Remedies is the second fastest growing company among the top 30 companies in the IPM in terms of domestic sales between MAT June 2022 and MAT June 2025. Over that period, domestic sales grew at a CAGR of 16.8% versus the IPM CAGR of 9.2%.

Another line states the company achieved domestic growth of 13.6% in MAT Jun 2024-25 versus IPM’s 8%, and delivered about 17% CAGR over FY22-25, described as 1.8 times IPM growth. The same excerpt says the company advanced its ranking from 37th to 29th among India’s top 30 pharmaceutical companies.

Recent-quarter commentary and governance flags in the dataset

The dataset notes Corona Remedies reported Q2 FY26 performance with stable revenue growth, supported by traction in chronic and sub-chronic therapies. It adds that domestic formulations continued to drive sales, reflecting consistent prescription demand across key brands.

Two additional points appear in the provided text as flags rather than quantified results: promoter holding decreased by 3.50% over the last quarter, and the company “might be capitalizing the interest cost.” These statements are not expanded with further details in the material provided, but they are part of the dataset and may be tracked by investors alongside operating performance.

Summary table of disclosed metrics

Why the numbers matter

The most consistent theme across the provided material is that Corona Remedies is growing faster than the broader IPM, particularly in domestic sales over the MAT June 2022 to MAT June 2025 period. The company’s portfolio mix moving further toward chronic and sub-chronic therapies, and the stated intent to expand into therapeutic areas such as nephrology, central nervous system, oncology, and dermatology through strategic acquisitions, supports this positioning.

Margin movement is also meaningful in the dataset, with EBITDA margin described as expanding from 14.5% to about 20% and PAT margin from 9.5% to 12.5%. Combined with the stated cash conversion metric (CFO/PAT 1.5277) and a three-year ROE above 25%, the figures indicate a business profile where growth is being accompanied by improved operating leverage, based on the numbers shared.

Conclusion

Corona Remedies’ FY26 disclosures and commentary point to India-led growth of around 17% and a year-on-year PAT increase of 33%, alongside outperformance versus IPM growth. The company has reiterated a medium-term framework of 15% revenue growth and 20% profitability growth, while outlining expansion plans through launches, in-licensing, and acquisitions. Investors will likely track how this guidance plays out in subsequent quarters, alongside the domestic mix, regional concentration, and any additional disclosures around promoter holding changes and interest cost treatment mentioned in the dataset.